Lineage Cell Therapeutics, Inc. (LCTX)

1.0600 +0.0100 (+0.95%) At close: 04:00PM EDT

Lineage Cell Therapeutics, Inc.

2173 Salk Avenue
Suite 200
Carlsbad, CA 92008
United States
442 287 8990
https://www.lineagecell.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 68

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Brian M. Culley M.A., M.B.A.	CEO, President & Director	986.7k	N/A	1971
Ms. Jill Ann Howe	CFO & Principal Financial and Accounting Officer	587.4k	N/A	1977
Mr. George A. Samuel III, J.D.	General Counsel & Company Secretary	554.51k	N/A	1981
Ioana C. Hone	Director of Investor Relations	N/A	N/A	N/A
Dr. Charlotte Hubbert Ph.D.	Vice President of Corporate Development	N/A	N/A	N/A
Ms. Brandi L. Roberts CPA, M.B.A.	Consultant	407.45k	N/A	1974
Mr. William Annett MBA	President & CEO of OncoCyte Corporation	53.2k	N/A	1954
Dr. Rami Skaliter Ph.D.	Chief Executive Officer of Cell Cure Neurosciences	N/A	N/A	1958
Ms. Alexandra Hernandez	Senior Director of Finance & Controller	N/A	N/A	N/A
Dr. Harold D. Waitz	Vice President of Regulatory Affairs & Quality Control	90k	N/A	1942

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Corporate governance

Lineage Cell Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2024 is 4. The pillar scores are Audit: 3; Board: 7; Shareholder rights: 2; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.